Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib-Reference-Cited by-同舟云学术

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

Published:2012-05-17 Issue:23 Volume:118 Page:5903-5911
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Goldman Jonathan W.,Laux Isett,Chai Feng,Savage Ronald E.,Ferrari Dora,Garmey Edward G.,Just Richard G.,Rosen Lee S.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27575/fullpdf

Reference31 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med.,2005

2. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol.,2007

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med.,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science.,2004

5. Erlotinib in lung cancer - molecular and clinical predictors of outcome;Tsao;N Engl J Med.,2005

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

2. Predictors of bradycardia in non-small-cell lung cancer patients receiving anaplastic lymphoma kinase inhibitors in a teaching hospital: A retrospective cohort study;2024-05-23

3. Design, synthesis, and biological evaluation of new biaryl derivatives of cycloalkyl diacetamide bearing chalcone moiety as type II c-MET kinase inhibitors;Molecular Diversity;2024-03-11

4. Design, Synthesis, and Biological Evaluation of New Biaryl Derivatives of Cycloalkyl diacetamide Bearing Chalcone Moiety as type II c-MET Kinase Inhibitors;2023-06-30

5. Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy;Journal of Medicinal Chemistry;2023-06-01